Until the 2000s, therapeutic options were limited and based upon high doses of the cytokines interleukin-2 (IL-2) and interferon, reflecting ccRCC sensitivity to immunotherapy. The gene discussed is IL2; the disease is nonpapillary renal cell carcinoma.